Presentation is loading. Please wait.

Presentation is loading. Please wait.

Whole Brain Radiotherapy and RRx-001: Two Partial Responses in Radioresistant Melanoma Brain Metastases from a Phase I/II Clinical Trial Michelle M. Kim,

Published byAmberlynn Wiggins Modified over 8 years ago

Similar presentations

Presentation on theme: "Whole Brain Radiotherapy and RRx-001: Two Partial Responses in Radioresistant Melanoma Brain Metastases from a Phase I/II Clinical Trial Michelle M. Kim,"— Presentation transcript:

1 Whole Brain Radiotherapy and RRx-001: Two Partial Responses in Radioresistant Melanoma Brain Metastases from a Phase I/II Clinical Trial Michelle M. Kim, Hemant Parmar, Yue Cao, Priyanka Pramanik, Matthew Schipper, James Hayman, Larry Junck, Aaron Mammoser, Jason Heth, Corey A. Carter, Arnold Oronsky, Susan J. Knox, Scott Caroen, Bryan Oronsky, Jan Scicinski, Theodore S. Lawrence, Christopher D. Lao Translational Oncology Volume 9, Issue 2, Pages 108-113 (April 2016) DOI: 10.1016/j.tranon.2015.12.003 Copyright © 2015 Terms and Conditions Terms and Conditions

2 Figure 1 Translational Oncology 2016 9, 108-113DOI: (10.1016/j.tranon.2015.12.003) Copyright © 2015 Terms and Conditions Terms and Conditions

3 Figure 2 Translational Oncology 2016 9, 108-113DOI: (10.1016/j.tranon.2015.12.003) Copyright © 2015 Terms and Conditions Terms and Conditions

4 Figure 3 Translational Oncology 2016 9, 108-113DOI: (10.1016/j.tranon.2015.12.003) Copyright © 2015 Terms and Conditions Terms and Conditions

5 Figure 4 Translational Oncology 2016 9, 108-113DOI: (10.1016/j.tranon.2015.12.003) Copyright © 2015 Terms and Conditions Terms and Conditions

6 Figure 5 Translational Oncology 2016 9, 108-113DOI: (10.1016/j.tranon.2015.12.003) Copyright © 2015 Terms and Conditions Terms and Conditions

Download ppt "Whole Brain Radiotherapy and RRx-001: Two Partial Responses in Radioresistant Melanoma Brain Metastases from a Phase I/II Clinical Trial Michelle M. Kim,"

Similar presentations

Genome Engineering with CRISPR-Cas9 in the Mosquito Aedes aegypti

Genome Engineering with CRISPR-Cas9 in the Mosquito Aedes aegypti
Irreplaceability of Neuronal Ensembles after Memory Allocation Naoki Matsuo Cell Reports Volume 11, Issue 3, Pages 351-357 (April 2015) DOI: 10.1016/j.celrep.2015.03.042.

Irreplaceability of Neuronal Ensembles after Memory Allocation Naoki Matsuo Cell Reports Volume 11, Issue 3, Pages (April 2015) DOI: /j.celrep
Treating the Developing versus Developed Brain: Translating Preclinical Mouse and Human Studies B.J. Casey, Charles E. Glatt, Francis S. Lee Neuron Volume.

Treating the Developing versus Developed Brain: Translating Preclinical Mouse and Human Studies B.J. Casey, Charles E. Glatt, Francis S. Lee Neuron Volume.
Distribution of Human Embryonic Stem Cell Lines: Who, When, and Where Jennifer B. McCormick, Jason Owen-Smith, Christopher Thomas Scott Cell Stem Cell.

Distribution of Human Embryonic Stem Cell Lines: Who, When, and Where Jennifer B. McCormick, Jason Owen-Smith, Christopher Thomas Scott Cell Stem Cell.
ER-to-Plasma Membrane Tethering Proteins Regulate Cell Signaling and ER Morphology Andrew G. Manford, Christopher J. Stefan, Helen L. Yuan, Jason A. MacGurn,

ER-to-Plasma Membrane Tethering Proteins Regulate Cell Signaling and ER Morphology Andrew G. Manford, Christopher J. Stefan, Helen L. Yuan, Jason A. MacGurn,
Two views of brain function Marcus E. Raichle Trends in Cognitive Sciences Volume 14, Issue 4, Pages 180-190 (April 2010) DOI: 10.1016/j.tics.2010.01.008.

Two views of brain function Marcus E. Raichle Trends in Cognitive Sciences Volume 14, Issue 4, Pages (April 2010) DOI: /j.tics
Choroidal Metastases Responsive to Crizotinib Therapy in a Lung Adenocarcinoma Patient with ALK 2p23 Fusion Identified by ALK Immunohistochemistry Yan.

Choroidal Metastases Responsive to Crizotinib Therapy in a Lung Adenocarcinoma Patient with ALK 2p23 Fusion Identified by ALK Immunohistochemistry Yan.
Prognostic Models Predicting Survival of Patients with Brain Metastases: Integration of Lactate Dehydrogenase, Albumin and Extracranial Organ Involvement.

Prognostic Models Predicting Survival of Patients with Brain Metastases: Integration of Lactate Dehydrogenase, Albumin and Extracranial Organ Involvement.
Feifei Teng, Christina I. Tsien, Theodore S. Lawrence, Yue Cao 

Feifei Teng, Christina I. Tsien, Theodore S. Lawrence, Yue Cao 
Risk of Pain Medication Misuse After Spinal Cord Injury: The Role of Substance Use, Personality, and Depression  Jillian M.R. Clark, Yue Cao, James S.

Risk of Pain Medication Misuse After Spinal Cord Injury: The Role of Substance Use, Personality, and Depression  Jillian M.R. Clark, Yue Cao, James S.
National Guidelines for Nursing Delegation

National Guidelines for Nursing Delegation
Breast-conserving therapy with partial or whole breast irradiation: Ten-year results of the Budapest randomized trial  Csaba Polgár, János Fodor, Tibor.

Breast-conserving therapy with partial or whole breast irradiation: Ten-year results of the Budapest randomized trial  Csaba Polgár, János Fodor, Tibor.
Adjuvant Therapy in High-Risk Stage III Cutaneous Melanoma

Adjuvant Therapy in High-Risk Stage III Cutaneous Melanoma
Hironori Yoshida, MD, Young Hak Kim, MD  Journal of Thoracic Oncology 

Hironori Yoshida, MD, Young Hak Kim, MD  Journal of Thoracic Oncology 
William L. Lanier, MD  Mayo Clinic Proceedings 

William L. Lanier, MD  Mayo Clinic Proceedings 
Alzheimer's disease drug development pipeline: 2018

Alzheimer's disease drug development pipeline: 2018
SYSTEMS-2: A randomised phase II study of radiotherapy dose escalation for pain control in malignant pleural mesothelioma  M. Ashton, N. O'Rourke, N.

SYSTEMS-2: A randomised phase II study of radiotherapy dose escalation for pain control in malignant pleural mesothelioma  M. Ashton, N. O'Rourke, N.
A Phase I Trial of the HIV Protease Inhibitor Nelfinavir with Concurrent Chemoradiotherapy for Unresectable Stage IIIA/IIIB Non-small Cell Lung Cancer:

A Phase I Trial of the HIV Protease Inhibitor Nelfinavir with Concurrent Chemoradiotherapy for Unresectable Stage IIIA/IIIB Non-small Cell Lung Cancer:
The Functional Gastrointestinal Disorders and the Rome III Process

The Functional Gastrointestinal Disorders and the Rome III Process
Redefining Clinical Trials: The Age of Personalized Medicine

Redefining Clinical Trials: The Age of Personalized Medicine

Similar presentations

Ads by Google